Integrated Continuous Protein and Conjugation Synthesis Platform


IC-PCS wants to address a major challenge in protein drug development: how can we make and screen biological drugs faster? Please check out our video below to learn more:

Description of the different modules

Go to Screening Modules

Screening Modules

Go to Computational modeling

Computational modeling

Check out latest research related to biologics drug development.

What makes this platform unique

A state-of-art platform for fast production and screening of biologics
Develop functionalized proteins for a wide range of applications.

Our Solution is two-fold: (1) Fail faster to succeed faster, and (2) eliminate harmful variations at the same time.

Overall objective is to shorten the preparation and evaluation of protein-based drugs several months to days. At the same time, we will built-in monitoring tools for process- and quality control at every step, and build translational computational models.

Future goal is to prepare 100+ drug candidates in one day, evaluate them, re-engineer and start again. Therefore, we will apply IC-PCS to develop, purify, formulate, and evaluate biological drugs on (i) toxicology, (ii) the interaction with the innate immune system, (iii) aggregation, (iv) adverse effects, and (v) binding to their respective targets (drug delivery).
More importantly, we will eliminate protein heterogeneity by providing feedback loops at every step in the process.

  • Modular platform

  • Protein drugs

  • in-vitro assays

  • Translational modeling


People actively involved in the project

Marco Casteleijn

Protein Engineering
PhD Research scientist.
Faculty of Pharmacy, Division of Pharmaceutical Biosciences & the Centre for Drug Research, University of Helsinki.

Léo Ghemtio

Computational modeling
PhD research scientist.
Faculty of Pharmacy, Division of Pharmaceutical Biosciences & the Centre for Drug Research, University of Helsinki.

Jaakko Itkonen

Protein Engineering
Doctoral Student.
Faculty of Pharmacy, Division of Pharmaceutical Biosciences, University of Helsinki.


Our collaborators

“What now?”: The most relevant further reading.

  • Kari, O. K., et al. "Multi-Parametric Surface Plasmon Resonance Platform for Studying Liposome-Serum Interactions and Protein Corona Formation." Drug Deliv Transl Res 7, no. 2 (Apr 2017)
  • Dumont, E., et al. "From near-Infrared and Raman to Surface-Enhanced Raman Spectroscopy: Progress, Limitations and Perspectives in Bioanalysis." Bioanalysis 8, no. 10 (May 2016)
  • Marco G. Casteleijn*, Dominique Richardson*. Engineering Cells and Proteins – creating pharmaceuticals. European Pharmaceutical Review, 19(4): 12-19 (2014)
  • Casteleijn, M. G., et al. "Expression without Boundaries: Cell-Free Protein Synthesis in Pharmaceutical Research." International Journal of Pharmaceutics 440, no. 1 (2013)
  • Legehar, A., et al. "Idaapm: Integrated Database of Admet and Adverse Effects of Predictive Modeling Based on Fda Approved Drug Data." J Cheminform 8 (2016)
  • Blog/Latest News

    Stay in touch with everything happening in the biologics world


    Happy to help